Goldman Sachs Remains a Buy on BridgeBio Pharma (BBIO)


Goldman Sachs analyst Paul Choi maintained a Buy rating on BridgeBio Pharma (BBIO) today and set a price target of $80.00. The company’s shares closed last Thursday at $49.59.

According to TipRanks.com, Choi is a 4-star analyst with an average return of 13.7% and a 51.2% success rate. Choi covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Silverback Therapeutics.

Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $82.00, implying a 56.0% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $86.00 price target.

See today’s analyst top recommended stocks >>

BridgeBio Pharma’s market cap is currently $7.39B and has a P/E ratio of -13.90. The company has a Price to Book ratio of 136.33.

Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BBIO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts